{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:50:50Z","timestamp":1764175850336,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jiac.2025.102807","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:58:51Z","timestamp":1757001531000},"page":"102807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Teicoplanin total trough concentration and adverse effects in patients with hypoalbuminemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Hirofumi","family":"Oishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-8008","authenticated-orcid":false,"given":"Yoshimichi","family":"Koutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narumi","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jiac.2025.102807_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0924-8579(94)90049-3","article-title":"A critical review of the dosage of teicoplanin in Europe and the USA","volume":"4","author":"Wilson","year":"1994","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102807_bib2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2015.02.002","article-title":"Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections","volume":"21","author":"Nakamura","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/j.1875-9114.1992.tb04516.x","article-title":"Teicoplanin nephrotoxicity: first case report","volume":"12","author":"Frye","year":"1992","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2025.102807_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0924-8579(98)00025-9","article-title":"Comparative safety of teicoplanin and vancomycin","volume":"10","author":"Wilson","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102807_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FTD.0b013e3180690755","article-title":"Variability in teicoplanin protein binding and its prediction using serum albumin concentrations","volume":"29","author":"Yano","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2025.102807_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","article-title":"Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study","volume":"43","author":"Roberts","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102807_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijantimicag.2015.01.015","article-title":"Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis","volume":"45","author":"Brink","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102807_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkx473","article-title":"Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy","volume":"73","author":"Byrne","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib10","first-page":"120","article-title":"Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients","volume":"74","author":"Yoshida","year":"2019","journal-title":"Pharmazie"},{"key":"10.1016\/j.jiac.2025.102807_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40360-020-00424-3","article-title":"Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 \u03bcg\/mL using a regimen of 12 mg\/kg for five doses within the initial 3 days","volume":"21","author":"Ueda","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jiac.2025.102807_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jiac.2025.102807_bib13","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1097\/CCM.0b013e3181de0b88","article-title":"Drug-induced thrombocytopenia in critically ill patients","volume":"38","author":"Priziola","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2025.102807_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2025.102807_bib15","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3748\/wjg.v27.i26.3984","article-title":"Acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"27","author":"Gupta","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiac.2025.102807_bib16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement\u2013induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2025.102807_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102807_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0034-1375956","article-title":"Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs","volume":"34","author":"Devarbhavi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jiac.2025.102807_bib19","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1007\/s00204-024-03773-8","article-title":"Investigation of parenteral nutrition-induced hepatotoxicity using human liver spheroid co-cultures","volume":"98","author":"Mihajlovic","year":"2024","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jiac.2025.102807_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.08.026","article-title":"The use of concomitant medications on nephrotoxicity associated with teicoplanin: a retrospective observational study","volume":"31","author":"Shimizu","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/abio.1995.1290","article-title":"A general, wide-rage spectrofluorometric method for measuring the site-specific affinities of drugs toward human serum albumin","volume":"227","author":"Epps","year":"1995","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jiac.2025.102807_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jsb.2006.08.015","article-title":"Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin","volume":"157","author":"Yang","year":"2007","journal-title":"J Struct Biol"},{"key":"10.1016\/j.jiac.2025.102807_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF01059273","article-title":"Pharmacokinetics of teicoplanin in man after intravenous administration","volume":"12","author":"Traina","year":"1984","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.jiac.2025.102807_bib24","first-page":"393","article-title":"Practice guidelines for therapeutic drug monitoring of antimicrobial drugs","volume":"60","year":"2012","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib25","first-page":"387","article-title":"Practice guidelines for therapeutic drug monitoring of antimicrobial drugs revised edition","volume":"64","year":"2016","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2025.102807_bib27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on Sepsis-related problems of the European society of intensive care medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jiac.2025.102807_bib28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1248\/bpb.b16-00930","article-title":"Analysis of adverse drug reaction risk in elderly patients using the Japanese adverse drug event report (JADER) database","volume":"40","author":"Chisaki","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2025.102807_bib29","first-page":"987","article-title":"Examination committee of criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for \u2018obesity disease\u2019 in Japan","volume":"66","year":"2002","journal-title":"Circ J"},{"key":"10.1016\/j.jiac.2025.102807_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12879-020-05719-8","article-title":"Combination of Sequential Organ Failure Assessment (SOFA) score and Charlson Comorbidity Index (CCI) could predict the severity and prognosis of candidemia more accurately than the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score","volume":"21","author":"Asai","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2025.102807_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01011-24","article-title":"Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality","volume":"13","author":"Guo","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiac.2025.102807_bib33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1177\/10600280221078123","article-title":"Thrombocytopenia associated with teicoplanin use: a retrospective observational study","volume":"56","author":"Elajez","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jiac.2025.102807_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","article-title":"Monitoring for hepatotoxicity: what is the predictive value of liver \u2018function\u2019 tests?","volume":"85","author":"Senior","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2025.102807_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health System Pharmacists, the Infectious Diseases Society of America, and the society of infectious diseases pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2025.102807_bib36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jiac.2025.102807_bib37","first-page":"453","article-title":"Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution","volume":"29","author":"Reinoso","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiac.2025.102807_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10156-006-0437-Z","article-title":"Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK\/TK)","volume":"12","author":"Yoshida","year":"2006","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102807_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet dysfunction in renal failure","volume":"30","author":"Boccardo","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jiac.2025.102807_bib40","first-page":"4385","article-title":"Serum uric acid and inflammation in patients with immune thrombocytopenic purpura: preliminary results","volume":"19","author":"Dal","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jiac.2025.102807_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijantimicag.2015.03.010","article-title":"Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: impact of albumin glycosylation on the binding of teicoplanin to albumin","volume":"46","author":"Enokiya","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102807_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1248\/yakushi.17-00023","article-title":"Effects of teicoplanin on the PT-INR controlled by warfarin in infection patients","volume":"137","author":"Nakano","year":"2017","journal-title":"Yakugaku Zasshi"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:26:08Z","timestamp":1759073168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1341321X25002041"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102807","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teicoplanin total trough concentration and adverse effects in patients with hypoalbuminemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102807"}}